| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellular Senescence | 17 | 2022 | 112 | 3.920 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2019 | 268 | 2.580 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 84 | 1.390 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 8 | 2022 | 134 | 1.250 |
Why?
|
| Reactive Oxygen Species | 11 | 2021 | 499 | 1.070 |
Why?
|
| Bone Marrow | 7 | 2014 | 168 | 1.030 |
Why?
|
| Microglia | 2 | 2022 | 143 | 0.950 |
Why?
|
| Interleukin-6 | 2 | 2022 | 330 | 0.920 |
Why?
|
| Imidazoles | 4 | 2013 | 175 | 0.900 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 35 | 0.890 |
Why?
|
| Stilbenes | 2 | 2013 | 57 | 0.880 |
Why?
|
| Radiation-Protective Agents | 2 | 2019 | 16 | 0.870 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2022 | 41 | 0.790 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2021 | 110 | 0.780 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 191 | 0.750 |
Why?
|
| Cell Proliferation | 9 | 2022 | 1174 | 0.730 |
Why?
|
| Apoptosis | 11 | 2019 | 1641 | 0.720 |
Why?
|
| NF-E2 Transcription Factor | 1 | 2019 | 2 | 0.710 |
Why?
|
| Hormesis | 1 | 2019 | 2 | 0.710 |
Why?
|
| DNA Damage | 5 | 2015 | 190 | 0.710 |
Why?
|
| Selenoproteins | 1 | 2019 | 4 | 0.700 |
Why?
|
| Hematopoiesis | 4 | 2015 | 108 | 0.680 |
Why?
|
| Whole-Body Irradiation | 7 | 2014 | 52 | 0.650 |
Why?
|
| Oxidative Stress | 5 | 2019 | 718 | 0.650 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 1172 | 0.630 |
Why?
|
| Phenanthrenes | 1 | 2017 | 18 | 0.610 |
Why?
|
| Antioxidants | 3 | 2015 | 304 | 0.610 |
Why?
|
| Diterpenes | 1 | 2017 | 42 | 0.600 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2009 | 22 | 0.590 |
Why?
|
| Cell Line, Tumor | 8 | 2022 | 1851 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 90 | 0.580 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 565 | 0.580 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2013 | 231 | 0.540 |
Why?
|
| Catalase | 1 | 2015 | 85 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 444 | 0.490 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 1070 | 0.460 |
Why?
|
| Radiation, Ionizing | 5 | 2021 | 37 | 0.460 |
Why?
|
| NADPH Oxidases | 3 | 2011 | 80 | 0.450 |
Why?
|
| Pyridines | 3 | 2012 | 261 | 0.440 |
Why?
|
| Mice | 20 | 2019 | 8474 | 0.440 |
Why?
|
| NF-kappa B | 3 | 2022 | 432 | 0.440 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2012 | 331 | 0.430 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1533 | 0.430 |
Why?
|
| Piperazines | 2 | 2013 | 206 | 0.420 |
Why?
|
| Hydrogen Peroxide | 2 | 2019 | 168 | 0.390 |
Why?
|
| Neoplasms | 2 | 2021 | 1664 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 13 | 2015 | 2791 | 0.390 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 30 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 6 | 2014 | 51 | 0.360 |
Why?
|
| Busulfan | 5 | 2010 | 13 | 0.360 |
Why?
|
| Animals | 21 | 2019 | 20880 | 0.320 |
Why?
|
| Humans | 26 | 2022 | 68549 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 332 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2008 | 223 | 0.300 |
Why?
|
| Cells, Cultured | 8 | 2015 | 2673 | 0.280 |
Why?
|
| MicroRNAs | 1 | 2010 | 447 | 0.260 |
Why?
|
| Fibroblasts | 4 | 2010 | 902 | 0.260 |
Why?
|
| Phosphorylation | 5 | 2013 | 1200 | 0.250 |
Why?
|
| Signal Transduction | 6 | 2015 | 2689 | 0.250 |
Why?
|
| Interleukin-18 | 2 | 2002 | 16 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2013 | 97 | 0.240 |
Why?
|
| Cell Cycle | 2 | 2010 | 312 | 0.240 |
Why?
|
| Flow Cytometry | 4 | 2013 | 489 | 0.230 |
Why?
|
| Intestine, Small | 1 | 2004 | 89 | 0.230 |
Why?
|
| Up-Regulation | 4 | 2012 | 682 | 0.230 |
Why?
|
| Nicotinamide N-Methyltransferase | 2 | 2022 | 2 | 0.230 |
Why?
|
| Plaque, Amyloid | 1 | 2022 | 31 | 0.210 |
Why?
|
| Sulfones | 1 | 2022 | 45 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 4 | 2017 | 852 | 0.210 |
Why?
|
| Nitriles | 1 | 2022 | 68 | 0.210 |
Why?
|
| Vaccines, DNA | 1 | 2001 | 9 | 0.200 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2001 | 12 | 0.200 |
Why?
|
| Leukemia | 2 | 2004 | 117 | 0.200 |
Why?
|
| beta-Galactosidase | 3 | 2013 | 88 | 0.190 |
Why?
|
| Gamma Rays | 2 | 2019 | 64 | 0.190 |
Why?
|
| Enzyme Activation | 3 | 2011 | 791 | 0.190 |
Why?
|
| Onium Compounds | 2 | 2011 | 4 | 0.190 |
Why?
|
| DNA Repair | 1 | 2021 | 127 | 0.180 |
Why?
|
| RNA Interference | 2 | 2019 | 266 | 0.180 |
Why?
|
| Acetylcysteine | 3 | 2013 | 296 | 0.180 |
Why?
|
| Enzyme Inhibitors | 4 | 2019 | 659 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 138 | 0.170 |
Why?
|
| Benzene Derivatives | 1 | 2019 | 12 | 0.170 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 40 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2017 | 238 | 0.170 |
Why?
|
| Organoselenium Compounds | 1 | 2019 | 17 | 0.170 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 434 | 0.170 |
Why?
|
| Isoflavones | 1 | 2019 | 31 | 0.170 |
Why?
|
| Bone Marrow Cells | 3 | 2012 | 217 | 0.170 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 80 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 331 | 0.170 |
Why?
|
| Sirtuin 1 | 1 | 2019 | 47 | 0.170 |
Why?
|
| Male | 14 | 2019 | 37283 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2011 | 245 | 0.150 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 20 | 0.150 |
Why?
|
| Cell Line | 4 | 2012 | 1752 | 0.150 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 45 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 304 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2007 | 57 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1745 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2013 | 954 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 1293 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 86 | 0.120 |
Why?
|
| Receptors, CXCR4 | 2 | 2013 | 48 | 0.120 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.120 |
Why?
|
| Ribonucleotide Reductases | 1 | 2013 | 9 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 37 | 0.120 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 24 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 209 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 82 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 261 | 0.110 |
Why?
|
| Genes, abl | 1 | 2012 | 4 | 0.110 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2012 | 15 | 0.110 |
Why?
|
| Time Factors | 4 | 2011 | 4655 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 118 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2013 | 87 | 0.110 |
Why?
|
| RNA, Messenger | 4 | 2005 | 1663 | 0.100 |
Why?
|
| Glutathione Disulfide | 1 | 2012 | 31 | 0.100 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2012 | 21 | 0.100 |
Why?
|
| Immune System | 1 | 2012 | 63 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1040 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 129 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 710 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2011 | 25 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 74 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 40 | 0.100 |
Why?
|
| Cell Transplantation | 1 | 2011 | 22 | 0.100 |
Why?
|
| Cisplatin | 1 | 2012 | 192 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2011 | 41 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 290 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2013 | 1692 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2010 | 63 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 300 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2010 | 137 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 189 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 157 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 13 | 0.090 |
Why?
|
| NADPH Oxidase 4 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 306 | 0.090 |
Why?
|
| Bridged-Ring Compounds | 2 | 2012 | 14 | 0.090 |
Why?
|
| Thiones | 2 | 2012 | 16 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2010 | 447 | 0.080 |
Why?
|
| Aged | 2 | 2022 | 14842 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2007 | 175 | 0.080 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 9 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2012 | 617 | 0.080 |
Why?
|
| Cyclins | 2 | 2004 | 50 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 753 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1034 | 0.070 |
Why?
|
| Female | 5 | 2019 | 38021 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 250 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p19 | 1 | 2005 | 5 | 0.070 |
Why?
|
| Cell Survival | 4 | 2013 | 901 | 0.060 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2004 | 12 | 0.060 |
Why?
|
| Genes, cdc | 1 | 2004 | 5 | 0.060 |
Why?
|
| Diploidy | 1 | 2004 | 7 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2004 | 22 | 0.060 |
Why?
|
| Cell Size | 1 | 2004 | 76 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 75 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2003 | 532 | 0.060 |
Why?
|
| Prodrugs | 1 | 2004 | 54 | 0.060 |
Why?
|
| Protein C | 1 | 2022 | 4 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 39 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Tyramine | 1 | 2022 | 16 | 0.050 |
Why?
|
| Membrane Fluidity | 1 | 2022 | 13 | 0.050 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2022 | 18 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2004 | 431 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2001 | 66 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2001 | 93 | 0.050 |
Why?
|
| Phenotype | 1 | 2004 | 946 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 135 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 118 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 331 | 0.050 |
Why?
|
| Point Mutation | 1 | 2001 | 97 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 159 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2001 | 215 | 0.040 |
Why?
|
| Pyrimidines | 2 | 2012 | 178 | 0.040 |
Why?
|
| Norbornanes | 2 | 2012 | 8 | 0.040 |
Why?
|
| Thiocarbamates | 2 | 2012 | 20 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 89 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 68 | 0.040 |
Why?
|
| Mammary Glands, Human | 1 | 2019 | 33 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 70 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 89 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 1446 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 567 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2019 | 222 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 799 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1174 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 508 | 0.030 |
Why?
|
| Ceramides | 2 | 2012 | 578 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 756 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 61 | 0.030 |
Why?
|
| Telomere | 1 | 2014 | 59 | 0.030 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2013 | 9 | 0.030 |
Why?
|
| GATA1 Transcription Factor | 1 | 2013 | 19 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 26 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2012 | 50 | 0.030 |
Why?
|
| Diglycerides | 1 | 2012 | 49 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2003 | 124 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 39 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 122 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 78 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2012 | 131 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 302 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 156 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 149 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2011 | 12 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 304 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Radiation | 1 | 2010 | 7 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 149 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2010 | 134 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 35 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 742 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 132 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 237 | 0.020 |
Why?
|
| Pyrroles | 1 | 2008 | 83 | 0.020 |
Why?
|
| ras Proteins | 1 | 2008 | 102 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 37 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 140 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 247 | 0.020 |
Why?
|
| Glutathione | 1 | 2007 | 343 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 21119 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 21379 | 0.020 |
Why?
|
| Esterases | 1 | 2004 | 9 | 0.010 |
Why?
|
| Drug Stability | 1 | 2004 | 71 | 0.010 |
Why?
|
| U937 Cells | 1 | 2004 | 61 | 0.010 |
Why?
|
| Genes, RAG-1 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 16 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2003 | 11 | 0.010 |
Why?
|
| Carbocyanines | 1 | 2003 | 13 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2004 | 144 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 34 | 0.010 |
Why?
|
| G1 Phase | 1 | 2003 | 42 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2003 | 1 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 34 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 84 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 160 | 0.010 |
Why?
|
| Drug Design | 1 | 2004 | 107 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 301 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2002 | 94 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 191 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 305 | 0.010 |
Why?
|
| Lung | 1 | 2007 | 849 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 329 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 492 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 658 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 770 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 597 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1549 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 2093 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 5720 | 0.010 |
Why?
|